United States · Series D startup
4 rounds we have observed, with the 8 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$171Mraised across 4 rounds since 2004, from 4 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
MPM Capital
Essex Woodlands Healthcare Partners
Aisling Capital
Blue Chip Venture CompanyFrom a historical funding record
MPM CapitalEssex Woodlands Healthcare PartnersAisling CapitalBlue Chip Venture CompanyReported by onbiovc.com
MPM Capital
Apax PartnersEssex Woodlands Healthcare PartnersAisling CapitalBlue Chip Venture CompanyFrom a historical funding record
From a historical funding record
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Essex Woodlands Healthcare PartnersMPM CapitalAisling CapitalBlue Chip Venture CompanyAIG InvestmentsUnion Spring PharmaceuticalsApax PartnersMissing a round, or an investor who was in one? Tell us.
Xanodyne's investors include HealthCare Ventures, Essex Woodlands Healthcare Partners, MPM Capital, Aisling Capital and Blue Chip Venture Company, and 3 more on record.
Xanodyne has raised $171M across 4 rounds since 2004.
Xanodyne's most recent round was a Series D of $88M in Oct 2009.
Its most recent round, $88M in Oct 2009, is also its largest on record.
Xanodyne's first round on record, in Jun 2004, was backed by HealthCare Ventures and Essex Woodlands Healthcare Partners.
Xanodyne's latest named round is a Series D, in Oct 2009.
Xanodyne is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States ·